Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists

US7709509B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Stefanie Keil · Frankfurt am Main, DE
• Wolfgang Wendler · Bad Camberg, DE
• Maike Glien · Frankfurt am Main, DE
• Jochen Goerlitzer · Frankfurt am Main, DE
• Karen Chandross · Somerville, US
• Daniel McGarry · King of Prussia, US
• Jean Merrill · Morristown, US
• Patrick Bernardelli · Fontenay-aux-Roses, FR
• Baptiste Ronan · Clamart, FR
• Corinne Terrier · Livry-Gargan, FR

Key dates

• Filing date: Jun 5, 2008
• Grant date: May 4, 2010
• Expiry date: Jun 5, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I,in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.